Driving neoantigen-based cancer vaccines for personalized immunotherapy into clinic: A burdensome journey to promising land
Open Access
- 1 August 2022
- journal article
- review article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 153, 113464
Abstract
No abstract availableKeywords
Funding Information
- Youth Science Fund Project (81901686)
- Youth Science Fund Project (82071796)
- National Natural Science Foundation of China
This publication has 106 references indexed in Scilit:
- Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trialThe Lancet Oncology, 2014
- Nanoparticles-based multi-adjuvant whole cell tumor vaccine for cancer immunotherapyBiomaterials, 2013
- Cancer Genome LandscapesScience, 2013
- Deciphering Signatures of Mutational Processes Operative in Human CancerCell Reports, 2013
- Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancerInternational Journal of Oncology, 2012
- Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoeditingNature, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Genetic associations in Italian primary sclerosing cholangitis: Heterogeneity across Europe defines a critical role for HLA-CJournal of Hepatology, 2010
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- DC-based cancer vaccinesJournal of Clinical Investigation, 2007